$ADRO weakness continues, and $ADXS teasing me. Low volume, I'm looking for serious sellers (including, potentially, the company itself).
1. Low volume- really
2. Looking for serious sellers- very few who are traders at this level (may be when MC of ADRO and ADXS equal you can get more)
3. Company to se sold- for over $6 billion and you will continue to short until then- your $10 million will not be enough to do so. .
Give it man. We are pounding those who are emotional and not rational. They think we are selling them ADXS. They should be smart enough to figure that out on their own. I know your intentions which are noble but some here do not think so because they have big EGOS. They bought because WS sold a clunker stamped with Neiman Marcus price.
In other words both of them are needed. But XON can use different engineered combos- are these host specific and cancer specific. Whenever you get a chance you can please expand.
Consequently, the index is not market cap weighted but rather equally weights each stock in the portfolio. This means that 24% of the index returns will be highly correlated to the overall biotech industry as one would expect from a collection of large caps. The remaining 75% of returns will come from the top 19 growth biotechnology companies in “cancer immunotherapy” by market capitalization as seen below:
n 2013, Goldman Sachs identified 8 disruptive technologies for investors to watch, among them 3D printing, LED Lighting and something called “cancer immunotherapy“. While this has been heavily followed by biotech investors in the past, the term is just now becoming more mainstream since Vice News published a special report on HBO last month titled “Killing Cancer” in which they generated a great deal of hype around some dramatically new ways to fight cancer that involve using viruses to provoke the immune system to attack cancer; measles for bone cancer, HIV for blood cancer, and the common cold virus for brain cancer. Researchers hope to find viruses that can kill the over 300 types of cancer that exist. And that’s just one way that ”cancer immunotherapy” uses the body’s own immune system to fight cancer.
While biotech investors have been watching the cancer immunotherapy “sector” closely, it’s just recently that many people are first hearing about this disruptive technology. The Vice Report claimed that the medical community is now ready to announce that we’re at the first stage to cure cancer. But why are we just now hearing about this? Because the medical community hasn’t been allowed to go public with the results until now, it’s happening in real time, it’s literally breaking news, etc. The report talked about the biggest success being the work of Dr. Carl Jun who has a 90% success rate using cancer immunotherapy methods to attack blood cancers. In an interview posted by the Cancer Research Institute, Dr. Jun talks in depth about some very promising early successes. After four years of ongoing trials, commercialization is expected to happen next year. Is this the “cure for cancer” everyone’s been waiting to invest in?
While the report generated a great deal of interest, experts felt the case by Vice was overstated. Nevertheless, cancer immunotherapy sounds like a promising field to invest in. Just a few weeks ago, the first cancer immunotherapy index, the Loncar Cancer Immunotherapy Index, was released moving this “sector” one step closer to investors. Quotes for the Loncar Cancer Immunotherapy Index can be found each day under the symbol “LCINDX” on the Bloomberg Professional service
thanks, i thought that is what he said. But with a loss of 293,000 over 1.1 Million just makes you humble but not cocky.
You are really expecting a dumb guy to know he is dumb. Let me put this way- he is dumb enough that he has no clue about it.
Not just you sir, but for most of us, including those who boast how good they are picking at stocks. I am glad that you stumbled on it in 01/2015 rather then in 2011 like me. #$%$ luck and makes you feel happy when others win.
Essentially, I'm willing to give back some gains in meantime for what I believe is a trade that should lead to further out-performance. $$
Apr. 23 at 5:06 PM
Slipping back: only up 1.05% net of fees vs. $SPY up 2.29%. YTD, though, I'm up 8.59% net of fees vs. about 3.19%. Why I'm giving ADXS room
bokka_raton • 37 minutes ago Flag
users liked this posts
users disliked this posts
SHORT will cover at 20 - This was biggest bubble ever, even ADXS garbage is better than this
This was easiest short of all, shorted at 45